Deoxyguanosine kinase Inhibitors
2 drugsAbout Deoxyguanosine kinase
Deoxyguanosine kinase (dGK) is an enzyme in the purine nucleoside salvage pathway, phosphorylating deoxyguanosine and related compounds. It plays a crucial role in nucleotide metabolism, maintaining the balance of deoxynucleotide pools for DNA synthesis and repair.
While there is currently no genetic evidence directly linking dGK to specific diseases, its role in nucleotide metabolism makes it a relevant target for drug development. Modulating dGK activity has potential therapeutic effects, as demonstrated by existing FDA-approved drugs.
Two FDA-approved drugs, NELARABINE (XGEN PHARMS) and ARRANON (Novartis), target dGK, both are small molecules. These drugs are used in 'other' therapeutic areas, highlighting the potential of dGK modulation.
Top Deoxyguanosine kinase Drugs
The competitive landscape consists of two companies, XGEN PHARMS and Novartis, with approved drugs.
Low market concentration suggests relatively low barriers to entry, but also highlights the limited commercial success to date.
Deoxyguanosine kinase Drug Modality Landscape
Modalities
Routes of Administration
Deoxyguanosine kinase is druggable by small molecules, though no oral formulations are currently approved.
The exclusive use of small molecules suggests an opportunity for novel modalities like antibodies or PROTACs to differentiate.
Deoxyguanosine kinase Clinical Trials 14 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Deoxyguanosine kinase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 2 | 2 | 1 | 50% |
| Phase 2 | 6 | 0 | 3 | 3 | 0% |
| Phase 3 | 3 | 1 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Deoxyguanosine kinase Drug Approval Timeline (2005 - 2021)
The first drug targeting dGK was approved in 2005 (ARRANON), with the most recent approval in 2021 (NELARABINE).
The 17-year span between approvals indicates slow progress and potential saturation, requiring a novel approach for future development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 11 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Deoxyguanosine kinase. A trial counts if an approved drug acting on Deoxyguanosine kinase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.